CBD Medical Plays to Watch

May 22, 2019 -- InvestorsHub NewsWire -- via microcapspeculators.com -- No matter what your stance on CBD is, you should be able to see the medical potential in the substance. GW Pharma did, and now has the first FDA approved CBD product.

One company with FDA approval history and an exciting new CBD product you should start researching right away is Innovus Pharmaceuticals, Inc. (USOTC: INNV). The company launched its first hemp-derived Cannabidiol product with MZS Sleeping Aid™. With Hemp being legal through the new Farm Bill, this makes companies like INNV even more enticing.

The companies we’re highlighting today include: Innovus Pharmaceuticals, Inc. (USOTC: INNV), Aurora Cannabis, Inc. (NYSE: ACB), ImmunoGen, Inc. (NASDAQ: IMGN), GW Pharmaceuticals plc (NASDAQ: GWPH), and Advaxis, Inc. (ADXS).

Innovus Pharmaceuticals, Inc. (USOTC: INNV) (Market Cap: $5.162M; Share Price: $2.00), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, has had quite the year:

2018 revenues of $24 million
Q1 2019 Revenues of approximately $5.4 million, an increase of $0.8 million or 18.0% compared to prior year and $0.6 million or 12.8% compared to the prior quarter
Sales & marketing expense as a percentage of total revenue declined to 48.4% compared with 72.7% in prior year
Annual product subscription and outbound concierge net revenue of $1.1 million compared to $0.6 million in the prior year or a 98.2% increase
Completed $3.17 million private placement
Cash used in operations of $0.6 million compared with $0.7 million in the prior year
Company's cash and merchant processor holdback position as of May 13, 2019 was $2.9 million
Annual 2019 net revenue projected to achieve record levels of $26-28 million

2019 First Quarter and Recent Corporate Progress:

Acquired assets of PrimeSavingsClub.com adding another revenue channel with recent historical annual revenues of $2.5 million
Diversified revenue channels resulting in approximately 30% of revenue derived from e-commerce platforms
Announced the FDA Approval of new ANDA for supply of FlutiCare which provides the Company with two suppliers of the product and the opportunity to use the dossier for international filings
Obtained approval of four products: Diabasens®, BH® Testosterone Booster, Xyralid® and RecalMax™ in Canada
Completed reverse stock split with an intention to potentially up list to Nasdaq
International partner, Lavasta Pharma receives approval from Algeria to market and sell Zestra® and Zestra Glide® and received a purchase order for $186,000
Announced a second partnered US ANDA for Minoxidil 5% Foam for men and women to be sold under the name Regoxidine™
Launched first hemp-derived Cannabidiol product with MZS Sleeping Aid™.

“We are encouraged by our start to the 2019 year with revenues increasing 18% and 12.8% in the comparable quarter in the prior year and the previous quarter, respectively. The company has been able to strategically diversify its revenue channels during the quarter without significant disruption to overall revenue and achieving revenues from e-commerce platforms by approximately 30%. Additionally, with twelve products now approved by Health Canada, we are poised to focus more marketing efforts in Canada where we have historically experienced superior returns which we believe will help us achieve our goal of profitability,” stated Bassam Damaj, President and Chief Executive Officer of Innovus Pharmaceuticals, Inc.

________

Aurora Cannabis, Inc. (NYSE: ACB) (Market Cap: $8.902B; Share Price: $8.66) reported a 20% jump in quarterly net revenue on Tuesday, as Canada's legalization of recreational cannabis late last year boosted demand.

The Edmonton, Alberta-based company's net revenue rose to C$65.2 million ($48.44 million) from C$54.2 million ($40.27 million) in the second quarter ($1 = 1.3459 Canadian dollars).

________

ImmunoGen, Inc. (NASDAQ: IMGN) (Market Cap: $291.585M; Share Price: $1.95) plunged more than 30% on Wednesday after the company revealed that the U.S. Food and Drug Administration has recommended further trials to "evaluate the safety and efficacy" of one of its cancer-fighting treatments. ImmunoGen said in statement that it had requested a meeting with FDA officials to discuss the results of its Phase 3 FORWARD I trial and a potential path to registration for mirvetuximab monotherapy - a treatment it has been developing for patients with certain forms of ovarian cancer.

________

GW Pharmaceuticals plc (NASDAQ: GWPH) (Market Cap: $5.662B; Share Price: $184.35) announced that Justin Gover, GW’s Chief Executive Officer, will present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019 at 8:00 a.m. PDT in Las Vegas.
________

Advaxis, Inc. (ADXS) (Market Cap: $23.137M; Share Price: $2.89), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.S. Food and Drug Administration (FDA or Agency) has lifted the partial clinical hold on AIM2CERV, the company’s Phase 3 clinical trial of axalimogene filolisbac (AXAL) for the treatment of patients with high-risk locally advanced cervical cancer. In its letter, the FDA acknowledged that the company satisfactorily addressed all hold questions.

Legal Disclaimer:

This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting has agreed to a three-month term consulting agreement with Innovus Pharmaceuticals, Inc. (USOTC: INNV) signed 05/20/2019. The agreement calls for $20,000 in cash and 10,000 restricted 144 shares per month. All payments were made directly by Innovus Pharmaceuticals, Inc. to Regal Consulting, LLC to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. INNV was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Full Legal Disclaimer Click Here.

Contact Information:

Company Name: ACR Communication LLC.

Contact Person: Media Manager

Email: info@microcapspeculators.com

Phone: 1-702-720-6310

Country: United States

SOURCE: microcapspeculators.com

Aurora Cannabis (NASDAQ:ACB)
Historical Stock Chart
From Mar 2024 to Apr 2024